Study on evaluation the incompatibility of modafinil with some excipients and solubility and dissolution rate25 views
Keywords:Modafinil; Smart drug; Nootropic drug; USP.
Modafinil has been used as ”smart drugs”, was manufactured by Cephalon Pharmaceutical Company, Pennsylvania. It was approved by the FDA in 1998 to treat narcolepsy. In previous studies, modafinil was easily synthesized in three stages via the Bunte salt intermediate, yield above 70%. The results of quality assessment of the product after synthesis met the requirements of USP 41. This article presented the results of research to evaluate the incompatibility of modafinil active ingredient with some excipients and solubility, dissolution rate of them, as the basis for preparation of modafinil in tablet form.
. Annas C. L., Annas G. J., “Enhancing the fighting force: Medical research on american soldiers”, Journal of Contemporary Health Law and Policy, 25 (2), pp. 283-308, (2009).
. Friedl K. E., “U. S. Army research on pharmacological enhancement of soldier performance: Stimulants, anabolic hormones, and blood doping”, Journal of Strenght and Conditioning Research”, 29 (11), pp. 71-76, (2015). DOI: https://doi.org/10.1519/JSC.0000000000001027
. Nguyễn Minh Trí và cộng sự, “Phương pháp mới để tổng hợp modafinil thông qua muối Bunte”, Tạp chí Hóa học, 58(5E12), tr.78-82, (2020).
. Nguyễn Minh Trí và cộng sự, “Quality evaluation of synthesized modafinil used as phamarceutical material”, Tạp chí Nghiên cứu Khoa học và Công nghệ quân sự, 77, trang 98-103, (2022). DOI: https://doi.org/10.58902/tcnckhpt.v2i1.34
. Dave V. S. et al., “Drug-excipent compatibility studies in formulation development: Current trends and Techniques”, Fisher Digital Publications, St. John Fisher University, 9 pages, (2015).
. Narang A. S., Rao V. M., Raghavan K. S., “Chapter 6 – Excipient Compatibility”, Developing Solid Oral Dosage Forms, pp. 125-145, (2009). DOI: https://doi.org/10.1016/B978-0-444-53242-8.00006-0
. Polaka S. et al., “Chapter 19 - Pharmaceutical excipient special focus on adverse interactions", Pharmacokinetics and Toxicokinetic Considerations, pp. 513-542, (2022). DOI: https://doi.org/10.1016/B978-0-323-98367-9.00009-3